Scleroderma is a connective-tissue disease that causes a progressive build up of tough scar-like tissue in the skin and internal organs. The term scleroderma is derived from the Greek words, skleros, meaning "hard," and derma meaning "skin." An individual with scleroderma may develop either a localized or systemic form of the disease. Localized scleroderma usually affects only the skin on the hands and face. Systemic scleroderma, however, affects the connective tissue in many parts of the body, including the skin, the esophagus, gastrointestinal tract, lungs, kidneys, heart, and other internal organs. It is unusual for localized scleroderma to progress to the systemic form. According to the Scleroderma Foundation, an estimated 300,000 people in the United States have the condition.
Symptoms of scleroderma may include one or more of the following:
Five particular symptoms occasionally occur together and are clinically recognized as a variation of scleroderma called CREST syndrome. The term CREST stands for Calcinosis (painful calcium deposits under the skin), Raynaud's phenomenon (abnormal sensitivity to cold in the hands and feet), Esophageal dysfunction (problems with swallowing caused by internal scarring), Sclerodactyly (tightening of the skin on the fingers or toes) and Telangiectasia (lesions on the hands, palms, forearms, face, and lips).
Scleroderma results from an overproduction of collagen, the primary connective tissue protein in the body. Scientists believe that the immune system mistakenly attacks the patient's own cells (an autoimmune response), producing too many white blood cells and other factors that cause a damaging inflammatory response and an overproduction of collagen, primarily in the skin. Researchers are not clear why this autoimmune response occurs, but they suggest that both genetic and environmental factors play a role in the development of the disease. For example, scleroderma has been associated with a number of industrial and pharmaceutical chemicals including:
The following factors may increase a person's risk for scleroderma:
An individual with symptoms of scleroderma will most likely require consultations with both a rheumatologist (arthritis specialist) and a dermatologist (skin specialist). The doctor will conduct a physical examination in which he or she may feel the skin, checking for thickened and hardened areas and may also press affected tendons and joints. The doctor may also conduct the following procedures to diagnose the disease:
Diagnosing scleroderma may be difficult, particularly in the early stages of the disease. This is because many individuals with scleroderma experience symptoms of other connective-tissue diseases, such as rheumatoid arthritis, lupus, and polymyositis. When these conditions overlap, it is called mixed connective-tissue disease.
It is important for an individual with scleroderma to avoid developing infections, so the physician will administer the following:
There is no cure for scleroderma. While medications are often used to treat the symptoms of the disease, they are not always effective, and many have significant side effects. There are, however, less toxic ways to treat the symptoms of scleroderma, such as lifestyle and dietary changes and the addition of dietary supplements, which make living with the disease easier.
|
While lifestyle adjustments will not stop the progression of scleroderma, these simple measures may enhance an individual's quality of life:
|
Localized scleroderma often is treated with topical therapies such as moisturizers or topical corticosteroids. Oral medications may also be used to halt the progression of localized scleroderma if it involves a large area of the body, such as an entire arm or leg. Systemic scleroderma may be treated with medications that improve circulation, promote gastrointestinal function, preserve kidney function, and control high blood pressure. Some medications a physician may prescribe for scleroderma include:
|
When symptoms of scleroderma become very severe, physicians may recommend the following procedures:
|
A comprehensive treatment plan for scleroderma may include a range of complementary and alternative therapies. Individuals with scleroderma tend to have deficiencies in many vitamins and minerals. Ask your team of health care providers about the best ways to incorporate these therapies into your overall treatment plan. Always tell your health care provider about the herbs and supplements you are using or considering using.
Following these nutritional tips may help reduce symptoms:
You may address nutritional deficiencies with the following supplements:
|
Herbs are generally a safe way to strengthen and tone the body's systems. As with any therapy, you should work with your health care provider to get your problem diagnosed before starting any treatment. You may use herbs as dried extracts (capsules, powders, teas), glycerites (glycerine extracts), or tinctures (alcohol extracts). Unless otherwise indicated, you should make teas with 1 tsp. herb per cup of hot water. Steep covered 5 - 10 minutes for leaf or flowers, and 10 - 20 minutes for roots. Drink 2 - 4 cups per day. You may use tinctures alone or in combination as noted.
|
A few studies of patients with systemic scleroderma indicate that acupuncture may improve circulation in the hands and fingers, mend fingertip ulcers, and possibly reduce the formation of fibrous tissue. Acupuncture may also be effective for pain.
|
Research suggests that massage may be useful in improving circulation and preventing muscle distortion. More research is needed in this area to determine whether massage is truly an effective complementary therapy for scleroderma.
|
Biofeedback appears to successfully control the temperature in the hands and feet of those with Raynaud's phenomenon, a symptom often found in those with scleroderma. Other mind-body techniques such as counseling, meditation, and emotional freedom technique (EFT) can be very useful.
|
Possible complications that may result from scleroderma include the following:
The prognosis for those with scleroderma is highly variable and depends primarily on the form of the disease. For example:
Amento EP. Immunologic abnormalities in scleroderma. Semin Cutan Med Surg . 1998;17(1):18-21.
Arlett CM et al Identification of fetal DNA and cells in skin lesions from women with systemic sclerosis. N Engl J Med . 1998;338(17):1186-91.
Barr WG. Current topics in the diagnosis and treatment of scleroderma. Compr Ther . 1991;17(6):39-45.
Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov . 2006;5(6):493-506.
Beers MH, Berkow R, eds. The Merck Manual of Diagnosis and Therapy . 17th ed. Whitehouse Station, NJ: Merck Research Laboratories; 1999. Section 5, Chapter 50.
Black CM. Prognosis and management of scleroderma and scleroderma-like disorders in children. Clin Exp Rheumatol . 1994;12(suppl 10):S75-81.
Black CM. Scleroderma in children. Adv Exp Med Biol . 1999;455:35-48.
Black CM. Scleroderma: clinical aspects. J Intern Med . 1993;234(2):115-8.
Burckdorfer KR, Hillary JB, Bunce T, et al. Increased susceptibility to oxidation of low-density lipoproteins isolated from patients with systemic sclerosis. Arthritis Rheum . 1995;38(8):1060-1067.
Casale R et al Systemic sclerosis (scleroderma): an integrated challenge in rehabilitation. Arch Phys Med Rehab . 1997;78(7):767-73.
Cunningham BB, Landells, IDR, Langman C, et al. Topical calcipotriene for morphea/linear scleroderma. J Am Acad Dermatol. 1998;39(2 Pt 1):211-215.
Cvetnic Z, Vladimir-Knezevic S. Antimicrobial activity of grapefruit seed and pulp ethanolic extract. Acta Pharm . 2004;54(3):243-50.
Elst EF, van Suijlekom-Smit LWA, Oranje AP. Treatment of linear scleroderma with oral 1,25-dihydroxyvitamin D 3 (calcitriol) in seven children. Pediatr Dermatol. 1999;16(1):53-58.
Gaby AR. The role of coenzyme Q10 in clinical medicine: Part 1. Alt Med Rev . 1996; 1(1):11-17.
Gelber AC, Wigley FM. Treatment of scleroderma. Curr Opin Rheumatol . 1995;7(6):551-9.
Gilliland BC. Systemic sclerosis (scleroderma). In: Fauci AS, Braunwald E, Isselbacher KJ, et al., eds. Harrison's Principles of Internal Medicine . 14th ed. New York, NY: McGraw-Hill; 1998:1888-1895.
Hale LP, Greer PK, Trinh CT, James CL. Proteinase activity and stability of natural bromelain preparations. Int Immunopharmacol . 2005;5(4):783-93.
Haustein UF, Anderegg U. Pathophysiology of scleroderma: an update . J Eur Acad Dermatol Venereol . 1998;11(1):1-8.
Herrick AL, Worthington H, Rieley F, et al. Dietary intake of micronutrient antioxidants in relation to blood levels in patients with systemic sclerosis. J Rheumatol. 1996;23(4):650-653.
Herrick AL. Advances in palliative care for the patient with scleroderma. Curr Opin Rheumatol . 1996;8(6):555-60.
Herron GS, Romero LI. Vascular abnormalities in scleroderma. Semin Cutan Med Surg . 1998;17(1):12-7.
Hunzelmann N et al. Management of localized scleroderma. Semin Cutan Med Surg . 1998;17(1):34-40.
Jimenez SA et al. Pathogenesis of scleroderma. Rheum Dis Clin North Am . 1996;22(4):647-74.
Kerin K, Yost JH. Advances in the diagnosis and management of scleroderma-related vascular complications. Compr Ther . 1998;24(11-12):574-81.
Krane SM, Amento EP. Cellular interactions and control of collagenase secretion in the synovium. J Rheumatol Suppl. 1983;11:7-12.
Lundberg A-C, Åkesson A, Åkesson B.Dietary intake and nutritional status in patients with systemic sclerosis. Ann Rheum Dis. 1992;51(10):1143-1148.
Maeda M, Kachi H, Ichihashi N et al. The effect of electrical acupuncture-stimulation therapy using thermography and plasma endothelin (ET-1) levels in patients with progressive system sclerosis (PSS). J Dermatol Sci. 1998;17(2):151-155.
Mayes MD. Scleroderma epidemiology. Rheum Dis Clin North Am . 1996;22(4):751-64.
McGee BA et al. Current options for the treatment of systemic scleroderma. Clin Pharm . 1991;10(1):14-25.
Miller M. Scleroderma. Aust Fam Physician . 1993;22(12):2112-9.
Mitchell H, et al. Scleroderma and related conditions. Med Clin North Am . 1997;81(1):129-49.
Muller-Ladner U, et al. Current therapy of systemic sclerosis (scleroderma). Clin Investig . 1993;71(4):257-63.
Murray MT. The Healing Power of Herbs: The Enlightened Person's Guide to the Wonders of Medicinal Plants. Rocklin, Calif: Prima Publishing; 1991:209.
Olsen NJ, et al. Muscle abnormalities in scleroderma. Rheum Dis Clin North Am . 1996;22(4):783-96.
Pang BK, Munro V, Kossard S. Pseudoscleroderma secondary to phytomenadione (vitamin K 1 ) injections: Texier's disease. Australas J Dermatol. 1996;37(1):44-47.
Rose S, et al. Gastrointestinal manifestations of scleroderma. Gastroenterol Clin North Am . 1998;27(3):563-94.
Schachter RK. Localized scleroderma. Curr Opin Rheumatol . 1990;2(6):947-55.
Sheng FY, Ohta A, Yamaguchi M. Inhibition of collagen production by traditional Chinese herbal medicine in scleroderma fibroblast cultures. Intern Med. 1994;33(8):466-471.
Shigematsu T, Tajima S, Nishikawa T, et al. Inhibition of collagen hydroxylation by lithospermic acid magnesium salt, a novel compound isolated from Salviae miltiorrhizae Radix. Biochem Biophys Acta . 1994:1200(1):79-83.
Silver RM. Scleroderma: clinical problems: the lungs. Rheum Dis Clin North Am . 1996;22(4):825-40.
Simopoulos AP. Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr . 2002;21(6):495-505.
Sjogren RW. Gastrointestinal features of scleroderma. Curr Opin Rheumatol . 1996;8(6):569-75.
Sjogren RW. Gastrointestinal motility disorders in scleroderma. Arthritis Rheum . 1994;37(9):1265-82.
Skibska B, Jozefowicz-Okonkwo G, Goraca A. Protective effects of early administration of alpha-lipoic acid against lipopolysaccharide-induced plasma lipid peroxidation. Pharmacol Rep . 2006;58(3):399-404.
Van den Hoogen FH, de Jong EM. Clinical aspects of systemic and localized scleroderma. Curr Opin Rheumatol . 1995;7(6):546-50.
Wang HK. The therapeutic potential of flavonoids. Expert Opin Investig Drugs . 2000;9(9):2103-19.
White B. Immunologic aspects of scleroderma. Curr Opin Rheumatol . 1995;7(6):541-5.
Wollina U, Abdel-Naser MB, Mani R. A review of the microcirculation in skin in patients with chronic venous insufficiency: the problem and the evidence available for therapeutic options. Int J Low Extrem Wounds . 2006;5(3):169-80.
Yoon JH, Baek SJ. Molecular targets of dietary polyphenols with anti-inflammatory properties. Yonsei Med J . 2005;46(5):585-96.
|
A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is the first of its kind, requiring compliance with 53 standards of quality and accountability, verified by independent audit. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial process . A.D.A.M. is also a founding member of Hi-Ethics (www.hiethics.com) and subscribes to the principles of the Health on the Net Foundation (www.hon.ch). |